Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- 488 Adverse Events, 48 Deaths Attributed to Alteplase
November 13, 2006
- FPMAJ, JPMA Call For Revision of Transfer Price Taxation System
November 13, 2006
- SURVEY 2 articles
November 13, 2006
- Coordination Essential for More Efficient Clinical Trials: JCROA Symposium
November 13, 2006
- Guerbet to Enhance Its Visibility in Japan
November 13, 2006
- REGULATORY NEWS IN BRIEF
November 13, 2006
- Korosho's Study Group on "Device Lag" Holds 1st Meeting
November 13, 2006
- TOPICS Diet Members with Cancer to Set Up Society
November 13, 2006
- Terumo: Double-digit Growth in Consolidated Sales, Profits
November 13, 2006
- Baxter to Provide Plasma/Albumin-Free Factor VIII to Hemophilia A Patients in Japan
November 13, 2006
- MEDICAL DEVICE NEWS IN BRIEF
November 13, 2006
- OPINION
November 6, 2006
- MD Devices, Diagnostics at Chuikyo
November 6, 2006
- NEW PRODUCTS
November 6, 2006
- MEDICAL DEVICE NEWS IN BRIEF
November 6, 2006
- Signa HDe, BrightSpeed Granted Good Design Awards: GE Yokogawa Medical System
November 6, 2006
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
November 6, 2006
- Call for Withdrawal from JPA Gathers Momentum among JACDS Members
November 6, 2006
- SEMINAR
November 6, 2006
- Import of Fludara Tab Recommended for Approval
November 6, 2006
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…